Lilly drug for
Alzheimer's fails to slow memory loss in big study
Send a link to a friend
[November 23, 2016]
(Reuters) - Eli Lilly and Co's
experimental drug failed to slow loss of cognitive ability in patients
with mild Alzheimer's disease in a large trial, a major setback for the
company and millions of people with the memory-robbing disease.
|
Shares of the U.S. drugmaker fell 13 percent in premarket trading.
Based on the failure of the Phase III study, Lilly said on Wednesday
that it would not seek U.S. approval of the infused drug for mild
dementia. Some analysts had said solanezumab, if approved, could
eventually claim more than $5 billion in annual sales and boost
Lilly's earnings for years to come.
Researchers said patients treated with solanezumab did not
experience a significantly greater slowing in cognitive decline than
those given placebos, as measured by a widely used scale called
ADAS-Cog14.
Lilly said it would take a $150 million charge in the fourth quarter
for the clinical setback and provide an updated 2016 financial
outlook, as well as 2017 forecasts, on Dec. 15.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
![](../images/ads/current/Symphony_122313.png)
![](http://archives.lincolndailynews.com/2016/Nov/23/images/ads/current/christian_church_lda_HFH_2016.png)
|